Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
June 13, 2026Neurology

Myasthenia Gravis Inebilizumab Trial (MINT): Efficacy, Pharmacodynamics, and Immunogenicity in AChR+ Cohort (Week 52) (S14.009)

View Full Paper
Ask AI
Bookmark
Share

Authors

KCKristen ClarksonKUKimiaki UtsugisawaMBMichael Benatar

Discussion

Loading...

Member takes

Overview

Randomized trial evaluates efficacy of inebilizumab in AChR+ generalized Myasthenia Gravis, suggesting potential benefits.

Key Points

  • This trial aims to assess the effectiveness and immune response of inebilizumab in treating generalized Myasthenia Gravis.
  • Evaluated efficacy, pharmacodynamics, and immunogenicity of inebilizumab in AChR+ individuals.
  • Focused on the week 52 outcomes in the inebilizumab treatment group.
  • Inebilizumab significantly improved muscle strength in AChR+ subjects, with clear pharmacodynamic effects.
  • Demonstrated favorable immunogenicity profile, indicating a low incidence of adverse immune responses.

Cite This Study

Clarkson et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3d6faef96ed7f0564d1https://doi.org/10.1212/wnl.0000000000216387
View Full Paper
Ask AI
Bookmark
Share